June 22, 2020, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that the American Association of Pharmaceutical Scientists (“AAPS”) has accepted two presentations regarding iCo’s Oral Amphotericin B technology (iCo-019) for the AAPS 2020 PharmSci 360 Meeting to be held October 26-November 5, 2020 (the “PharmSci 360 Meeting”).

AAPS is the preeminent global scientific organization of more than 10,000 actively participating pharmaceutical scientists from industry, academia, government, and other related research institutes.  The mission of AAPS is to advance the capacity of pharmaceutical scientists to develop medicines that improve health.

The full PharmSci 360 Meeting program – including posters – will be available online over a two-week period.  The virtual program is tentatively scheduled to include an in-person component held in New Orleans, Louisiana, USA October 26-28, 2020.

Dr. Kishor M. Wasan, Director of Research at iCo Therapeutics Inc. and Adjunct Professor and Distinguished University Scholar in the Faculty of Pharmaceutical Sciences at the University of British Columbia, stated “We are very pleased to be selected to present our research at this prestigious event and discuss our technology with so many in the pharmaceutical science community.”  Dr. Wasan, along with co-authors Drs. Peter Hnik and Ellen Wasan, will present the following two poster presentations:

Phase Ia and Ib Double-Blind Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (ICO-019) in Healthy Human Subjects

Assessing the Pharmacokinetics and Biodistribution of Amphotericin B following Oral Administration of Three Novel Oral Amphotericin B Formulations to Beagle Dogs.

In addition, Dr. Wasan will be leading an AAPS sponsored webinar in late September 2020 highlighting the accomplishments of the oral amphotericin B program to date.  More information about this webinar will be distributed by AAPS shortly.

“Despite the current COVID-19 pandemic there continues to be a great deal of interest in iCo-019 for the treatment of fungal and parasitic infections.  We have had a number of positive discussions with potential partners to help further the clinical development of iCo-019“, noted Dr. Wasan.

“In addition to recent activities involving publications and presentations of data from previous trials, iCo is actively preparing for the Phase 2 clinical study in vulvovaginal candidiasis (VVC).  The Covid-19 pandemic has generally affected clinical trials world-wide and the initiation of any trial will depend on the Covid-19 situation” stated Dr. Peter Hnik, iCo’s Chief Medical Officer.

About iCo Therapeutics

iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so the Company will seek to capture further value via partnerships. iCo shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.

For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

Certain statements included in this press release may be considered “forward-looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by words such as: “anticipate”, “intend”, “plan”, “goal”, “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include statements relating to the timing and completion of the Private Placement and the use of proceeds therefrom. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations
iCo Therapeutics Inc.
1-604-800-9860